Patents Assigned to ARECOR LIMITED
-
Patent number: 11608357Abstract: There is provided, inter alia, an aqueous solution comprising (i) an antibody protein; and (ii) a antibody protein stabilizing mixture of arginine, methionine, and a C3 polyol.Type: GrantFiled: August 27, 2019Date of Patent: March 21, 2023Assignee: ARECOR LIMITEDInventors: Jan Jezek, Luca Badiali, David Gerring
-
Patent number: 11534403Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, arginine and/or methionine, and a small polyol stabiliser such as glycerol. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.Type: GrantFiled: March 6, 2018Date of Patent: December 27, 2022Assignee: ARECOR LIMITEDInventors: Luca Badiali, David Gerring, Jan Jezek
-
Patent number: 11534402Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, EDTA, and a small polyol stabiliser such as glycerol. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.Type: GrantFiled: March 6, 2018Date of Patent: December 27, 2022Assignee: Arecor LimitedInventors: Luca Badiali, David Gerring, Jan Jezek
-
Patent number: 11278624Abstract: According to the invention there is provided inter alia an aqueous liquid pharmaceutical formulation comprising insulin or an insulin analogue, ionic zinc, a chelating agent and polysorbate 80.Type: GrantFiled: September 29, 2017Date of Patent: March 22, 2022Assignee: ARECOR LIMITEDInventors: David Gerring, Leon Zakrzewski, Jan Jezek, Sarah Howell
-
Patent number: 10925965Abstract: The invention relates to the discovery that the addition of aromatic carboxylate ions inhibit protein instability caused by aromatic preservatives. Thus, the invention relates to compositions, preferably aqueous compositions, comprising a protein, an aromatic preservative and aromatic carboxylate ions. The proteins remain stable and suitable for storage at ambient temperatures or lower, even in aqueous form. Preferably, the aqueous composition comprises a protein, a phenolic preservative and benzoate ions, wherein the pH of the composition is at least 1 unit greater than the pKa of benzoic acid. The invention also provides methods of reducing protein degradation by aromatic preservatives in an aqueous formulation of a protein susceptible to such degradation, comprising the step of adding aromatic carboxylate ions to the formulation wherein the formulation is maintained at a pH that is at least 1 unit greater than the pKa of the corresponding aromatic carboxylic acid.Type: GrantFiled: August 22, 2012Date of Patent: February 23, 2021Assignee: Arecor LimitedInventors: Jan Jezek, Barry Kingston Derham
-
Patent number: 10532098Abstract: The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine, wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range n=2-12.Type: GrantFiled: January 30, 2013Date of Patent: January 14, 2020Assignee: Arecor LimitedInventors: Jan Jezek, Guy Casy, Barry Kingston Derham, Nikki Royle
-
Publication number: 20180078645Abstract: According to the invention there is provided inter alia an aqueous liquid pharmaceutical formulation comprising insulin or an insulin analogue, ionic zinc, a chelating agent and polysorbate 80.Type: ApplicationFiled: September 29, 2017Publication date: March 22, 2018Applicant: Arecor LimitedInventors: David GERRING, Leon Zakrzewski, Jan Jezek, Sarah Howell
-
Patent number: 9744242Abstract: The present invention is based on the surprising discovery that the inclusion of an anionic polymer in the adenovirus formulation enhances long-term stability of the vector composition. An aqueous formulation comprising an adenovirus vector and at least one anionic polymer is provided, together with methods of the preparation of a storage stable adenovirus aqueous formulation.Type: GrantFiled: January 5, 2016Date of Patent: August 29, 2017Assignee: Arecor LimitedInventors: Jan Jezek, Angela Buckler
-
Publication number: 20170202954Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).Type: ApplicationFiled: January 30, 2017Publication date: July 20, 2017Applicant: Arecor LimitedInventor: Jan JEZEK
-
Publication number: 20160199496Abstract: The present invention is based on the surprising discovery that the inclusion of an anionic polymer in the adenovirus formulation enhances long-term stability of the vector composition. An aqueous formulation comprising an adenovirus vector and at least one anionic polymer is provided, together with methods of the preparation of a storage stable adenovirus aqueous formulation.Type: ApplicationFiled: January 5, 2016Publication date: July 14, 2016Applicant: Arecor LimitedInventors: Jan Jezek, Angela Buckler
-
Patent number: 9254332Abstract: The present invention is based on the surprising discovery that the inclusion of an anionic polymer in the adenovirus formulation enhances long-term stability of the vector composition. An aqueous formulation comprising an adenovirus vector and at least one anionic polymer is provided, together with methods of the preparation of a storage stable adenovirus aqueous formulation.Type: GrantFiled: March 13, 2014Date of Patent: February 9, 2016Assignee: Arecor LimitedInventors: Jan Jezek, Angela Buckler
-
Patent number: 9005611Abstract: A composition comprises a biological molecule that is susceptible to aggregation, dimerization or hydrolysis, wherein the ionic strength is less than 40 mM.Type: GrantFiled: October 28, 2010Date of Patent: April 14, 2015Assignee: Arecor LimitedInventor: Jan Jezek
-
Publication number: 20150010548Abstract: The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine, wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range n=2-12.Type: ApplicationFiled: January 30, 2013Publication date: January 8, 2015Applicant: Arecor LimitedInventors: Jan Jesek, Guy Casy, Barry Derham, Nikki Royle
-
Publication number: 20140348876Abstract: The present invention is based on the surprising discovery that the inclusion of an anionic polymer in the adenovirus formulation enhances long-term stability of the vector composition. An aqueous formulation comprising an adenovirus vector and at least one anionic polymer is provided, together with methods of the preparation of a storage stable adenovirus aqueous formulation.Type: ApplicationFiled: March 13, 2014Publication date: November 27, 2014Applicant: Arecor LimitedInventors: Jan JEZEK, Angela Buckler
-
Patent number: 8796210Abstract: An aqueous composition comprising a therapeutic protein further characterized in that (i) the pH of the composition is adjusted to be between about 5.9 and 6.3, preferably about 6.1; (ii) the composition comprises at least one displaced buffer having a pKa within 1 to 3 pH units of the pH of the composition; (iv) the osmolarity of the composition is between 150-500 mOsm/L.Type: GrantFiled: August 5, 2010Date of Patent: August 5, 2014Assignee: Arecor LimitedInventor: Jan Jezek
-
Patent number: 8486388Abstract: An aqueous composition which comprises a protein or other biological molecule and also (i) optionally comprises one or more metal ions at a concentration of 0.01 to 20 mM; (ii) comprises excipients which are weak ligands; and (iii) is substantially free of excipients which are medium-strength ligands, and is substantially free of excipients which are strong ligands in free form.Type: GrantFiled: October 28, 2010Date of Patent: July 16, 2013Assignee: Arecor LimitedInventor: Jan Jezek
-
Publication number: 20090148406Abstract: An aqueous system comprises a protein and one or more stabilising agents, characterised in that (i) the one or more stabilising agents have ionisable groups capable of exchanging protons with the protein and with the ionised products of water dissociation; (ii) the ionisable groups include first groups that are positively charged when protonated and uncharged when deprotonated, and second groups that are uncharged when protonated and negatively charged when deprotonated; and (v) the pH of the composition is within a range of protein stability that is at least 50% of the maximum stability of the protein with respect to pH.Type: ApplicationFiled: July 3, 2006Publication date: June 11, 2009Applicant: ARECOR LIMITEDInventor: Jan Jezek